Answers are grounded in this paper and cite their sources.
Review outlines a grading system for managing neurotoxicity in patients receiving immune therapy, suggesting improved outcomes.
The American Society for Transplantation and Cellular Therapy (ASTCT) developed this consensus grading system based on prior Common Terminology Criteria for Adverse Events (CTCAE) and Immune Effector Cells Therapy Toxicity Assessment and Management (CARTOX) grading systems. Grade of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) should guide management.
No takes yet. Share an insight, caveat, or question.
Austin Wesevich (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: